


WEILL CORNELL MEDICAL COLLEGE CURRICULUM VITAE FORM
(REQUIRED FORMAT)

Signature (required):	
Version date:	June 6, 2016

A. GENERAL INFORMATION

Required Information:

Name: First, Middle, Last	Timothy A. Chan
Office address:	Human Oncology and Pathogenesis Program Memorial Sloan-Kettering Cancer Center 1275 York Avenue Box 20 New York, NY 10065
Office telephone:	(646) 888-2765
Office fax:	(646) 888-2595

B. EDUCATIONAL BACKGROUND

1. Academic Degree(s): B.A. and higher; institution name and location; dates attended; date of award. Expand the table as needed.

Degree (abbreviation)	Institution Name and Location	Dates attended	Year Awarded
A.B. in biochemistry (<i>summa cum laude</i>)	Harvard College Cambridge, MA	September 1991 to June 1995	1995
Ph. D. in genetics	Johns Hopkins School of Medicine Baltimore, MD (PI: Dr. Bert Vogelstein)	September 1995 to June 2002	2002
M. D.	Johns Hopkins School of Medicine Baltimore, MD	September 1995 to June 2002	2002

2. Post-doctoral training (include residency/fellowships): In chronological order beginning with post-doctoral training positions; include full titles, ranks and inclusive dates held. Expand the tables as needed.

Title	Institution name and location	Dates held
Intern (Internal Medicine)	Medicine, Mercy Hospital/University of Maryland Baltimore, MD	2002-2003

Residency	Radiation Oncology, Johns Hopkins Hospital Baltimore, MD	2003-2007
Post-doctoral Research Fellowship	Division of Tumor Biology, Johns Hopkins Cancer Center Baltimore, MD (PI: Dr. Stephen Baylin)	2006-2007
Teaching Fellow – Biochemistry and Cell Biology	Harvard University Cambridge, MA	January 1994-January 1995
Teaching Fellow – Molecular Biology	Harvard University Cambridge, MA	September 1994-January 1995
Teaching Assistant – Pathology and Pathophysiology	Johns Hopkins School of Medicine Baltimore, MD	September 1998-June 1999
Teaching Assistant – Histology	Johns Hopkins School of Medicine Baltimore, MD	1999-2000

3. Continuing Medical Education Courses/Certificates

Certificate or Course	Institution Name and Location	Dates attended
Maintenance of Certification	American Board of Radiology	2009-present (up to date)

4. Other Educational Experiences

Description	Institution Name and Location	Dates attended
Certification of Completion in Infection Control	Memorial Sloan Kettering Approved Course	November, 2015

C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

- Licensure: Every physician appointed to the Hospital staff, except interns, and aliens in the US via non-immigrant visas, must have a New York State license or a temporary certificate in lieu of the license.

a. State	Number	Date of issue	Date of last registration
New York			

D. PROFESSIONAL POSITIONS AND EMPLOYMENT

- Academic positions (teaching and research)

Title	Institution name and location	Dates held
Assistant Member Level 1	Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program New York, NY	August 2007-2009
Assistant Member	Memorial Sloan-Kettering Cancer Center, Human Oncology and	August 2009-August 2012

	Pathogenesis Program New York, NY	
Assistant Professor	Memorial Sloan-Kettering Cancer Center; Gerstner-Sloan Kettering Graduate School of Biomedical Sciences New York, NY	April 2008- August 2012
Assistant Professor	Department of Cell and Developmental Biology, Weill Cornell School of Medicine	February 2011- August 2012
Associate Member	Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program New York, NY	September 2012 – present
Associate Professor	Memorial Sloan-Kettering Cancer Center; Gerstner-Sloan Kettering Graduate School of Biomedical Sciences New York, NY	September 2012 – present
Associate Professor	Department of Cell and Developmental Biology, Weill Cornell School of Medicine	September 2012 – present
Director of the Division of Translational Oncology	Memorial Sloan-Kettering Cancer Center; Department of Radiation Oncology New York, NY	August 2013 – present
Member/Professor Attending Physician	Memorial Sloan-Kettering Cancer Center, Human Oncology and Pathogenesis Program New York, NY	May 2016 - present

2. Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held
Chief Resident	Department of Radiation Oncology, Johns Hopkins Hospital Baltimore, MD	July 2006- July 2007
Assistant Attending Physician	Memorial Sloan-Kettering Cancer Center; Department of Radiation Oncology New York, NY	August 2007-August 2012
Co-Director, Benign Tumor Radiosurgery Service	Memorial Sloan-Kettering Cancer Center New York, NY	October 2009- present
Associate Attending Physician	Memorial Sloan-Kettering Cancer Center; Department of Radiation Oncology New York, NY	September 2012 – present
Vice Chair	Memorial Sloan-Kettering Cancer Center; Department of Radiation Oncology New York, NY	August 2013 – present

3. Other Employment

Title	Institution name and location	Dates held
Research Assistant	Department of Biochemistry and Molecular Biology, University of California Irvine, CA (PI: Dr. Robert Steele)	June 1989-August 1991
Research Assistant	Department of Biology, Indiana University Bloomington, IN (PI: Dr. Milton Taylor)	June 1992-August 1992
Research Assistant	Department of Biochemistry, Harvard University Cambridge, MA (Dr. Guido Guidotti)	October 1991-June 1992
Research Assistant	Program in Molecular Biology and Biotechnology, University of North Carolina Chapel Hill, NC (PI: Dr. William Marzluff)	June 1993-September 1993
Research Assistant	Cold Spring Harbor Laboratory Cold Spring Harbor, NY (Dr. David Beach)	June 1994-September 1994
Research Assistant	Department of Molecular and Cellular Biology, Harvard University Cambridge, MA (PI: Dr. Daniel Jay)	June 1993-August 1995
Co-founder	Gritstone Oncology (company that focuses on developing neoantigen-based cancer vaccines)	Oct. 2015-present

E. EMPLOYMENT STATUS (current or anticipated)

Name of Employer(s): Full Time Memorial Hospital for Cancer and Allied Disease
Employment Status (choose one, delete the others): Full-time salaried by Memorial Sloan Kettering Cancer Center

F. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Disease
2. Other Hospital Affiliations:	None
3. Other Institutional Affiliations:	None

G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES

CURRENT % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)
TEACHING	9	Y
CLINICAL	20	Y
ADMINISTRATIVE	1	N
RESEARCH	70	Y
TOTAL	100%	

FOR NEW WCMC FACULTY: IT IS VERY HELPFUL TO HAVE THIS TABLE REPEATED, SO THAT THE COMMITTEE OF REVIEW CAN SEE THE EXPECTED RESPONSIBILITIES AND EFFORT AT WCMC

WCMC ANTICIPATED % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)
TEACHING		
CLINICAL		
ADMINISTRATIVE		
RESEARCH		
TOTAL	100%	

INSTITUTIONAL RESPONSIBILITIES

1. Teaching (e.g., specific teaching functions, courses taught, dates: For guidance refer to [Teaching Metrics table](#). Report your teaching activities in the 4 areas of teaching shown below. To provide a more detailed teaching report, use the [Teaching Activities Report template](#) or [Educator Portfolio template](#) (strongly encouraged). Refer to it here as an attachment (e.g., see attached), and attach it to the CV.

<u>Didactic teaching:</u> (e.g., lectures, continuing medical education courses, grand rounds, professional development programs, seminars, tutorials)	
Teaching Fellow: Biological Sciences 11 – Biochemistry and Cell Biology Gave lectures, ran discussion sections, graded tests and assignments Harvard University	Dates 1994, spring semester 1995, spring semester
Teaching Fellow: Biological Sciences 10 – Molecular Biology Gave lectures, ran discussion sections, graded tests and assignments Harvard University	1994, fall semester
Teaching Assistant: Pathology and Pathophysiology (medical school year 2 course); Conducted teaching sections and presented lectures for medical and graduate students John Hopkins School of Medicine	9/1998-3/1999
Teaching Assistant: Histology (medical school year 1 course) Taught medical students basic histology. John Hopkins School of Medicine	12/1998-4/1999
Chief Resident: Teaching medical students, junior residents on service (radiation oncology) at the Johns Hopkins Hospital Organizing and giving Radiation Oncology departmental lecture series (year long) Organizing Grand Rounds for the Dept. of Radiation Oncology Administration of house staff rotation and call schedules (20% effort) John Hopkins Hospital	2006-2007

<p>Involves MSKCC radiation oncology residents, WMC medical students, MSK radiation therapist students, WMC graduates students, GSK graduate students (10% effort)</p> <p>Memorial Sloan Kettering Cancer Center</p> <ol style="list-style-type: none"> 1. Attending Physician teaching: Teaching radiation oncology residents and medical students on CNS service (every week, all year round); Supervising residents on treating patients with brain malignancies (MSK radiation oncology house staff and fellows, Cornell medical students) 2. Radiation Oncology Departmental lecture series (CNS block), includes multiple lectures and case conferences. Dates: 11/1/2007-11/30/2007, 10/1/2008-10/30/2009, 3/2010-4/2010, 1/2011-2/2011, 2012-2016 (MSK radiation oncology house staff and fellows, Cornell medical students) 3. Radiation Therapist Lecture Series (MSKCC) Lecture to the MSKCC radiation therapy students on the treatment of brain tumors 2007-present (Involves radiation therapy students) 4. Gerstner Graduate School Cancer Biology Course (MSKCC) Principles of Radiation Therapy 4/30/2008, 4/30/2009 Introduction to Epigenomics 2010, 2011, 2012, 2013, 2014, 2015 (GSK graduate students) 5. Radiation Oncology Grand Rounds Making Inroads into the Cancer Genome 2008 Tumor Profiling for Clinicians 2010 (MSK faculty, house staff, and fellows) 6. Medical Oncology Fellow Cancer Biology Course Give lectures and discussion sessions on the tumor suppressors section 5/2010, 5/2011, 2/2012, 2013, 2014, 2015 (MSK medical oncology fellows) 7. Dept. of Surgery Research Grand Rounds Biomarker Discovery Using Genomics 2007, 2009 (MSK surgical fellows and residents) 8. Trends in Modern Cancer Research Finding Needles in the Haystack: Making Inroads into the Cancer Genome Annual community outreach lecture on behalf of MSKCC 2010 9. Geoffrey Beene Cancer Center Annual Retreat lectures 5/2008, 5/2010 10. Dept. of Surgery Summer Course for fellows Genome-scale analysis, TCGA, and sample quality 9/2011, 2015 11. Radiation Oncology Dept. Cancer Biology Course Tumor Profiling for Clinicians Summer, 2013 	<p>8/2007-present</p>
--	-----------------------

Mentorship: (e.g., mentor for medical student, graduate student, resident, clinical or postdoctoral research fellow or junior faculty projects; service as graduate student thesis advisor or committee member)	
See attached table at end of CV	
Clinical teaching: (e.g., teaching in the clinic or hospital including bedside teaching, teaching in the operating room, preceptor in clinic)	
Chief Resident: Teaching medical students, junior residents on service (radiation oncology) at the Johns Hopkins Hospital Organizing and giving Radiation Oncology departmental lecture series (year long) Organizing Grand Rounds for the Dept. of Radiation Oncology Administration of house staff rotation and call schedules (20% effort) John Hopkins Hospital	Dates 2006-2007
Attending Physician teaching: Teaching radiation oncology residents and medical students on CNS service (every week, all year round); Supervising residents on treating patients with brain malignancies (MSK radiation oncology house staff and fellows, Cornell medical students) Memorial Sloan Kettering Cancer Center	8/2007-present
Administrative teaching leadership role: (e.g., residency or fellowship director, course or seminar director or co-director)	
Brain Tumor Center Seminar Director, MSKCC	2011-2012 2012-2013
Radiation Oncology Grand Rounds Co-Director, MSKCC	2013-2014
Radiation Oncology Dept. Cancer Biology Course Tumor Profiling for Clinicians MSKCC	2013
Chief Resident: Teaching medical students, junior residents on service (radiation oncology) at the Johns Hopkins Hospital Organizing and giving Radiation Oncology departmental lecture series (year long) Organizing Grand Rounds for the Dept. of Radiation Oncology Administration of house staff rotation and call schedules (20% effort) John Hopkins Hospital	2006-2007
Education Committee, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center	2007-present

2. Clinical care (duties, dates): To document clinical activities use the table below or, to document extensive clinical activities use the [Clinical Portfolio template](#) (strongly encouraged). Refer to it here as an attachment and attach it to the CV.

Examples: Clinical Activity; Clinical Program Development; Clinical Evaluations; Clinical Quality/Committees; Clinical Quality/Leadership Roles; Advocacy/Community Projects/Media/Public Education; Advising and Mentoring; Clinical Scholarship; Professional Educational Development; Clinical Honors and Awards	Dates
Attending Physician – Dept. of Radiation Oncology Patient care 20% effort 1. Outpatient clinic (1 day/wk) 2. Perform Stereotactic Radiosurgery brain procedures and brain tumor radiation	8/2007-present

<p>treatments (1 day/wk) (every week, all year round)</p> <p>3. Oversee treatment of patients with brain tumors</p> <p>4. On-call radiation oncology consult service (one week q 3 months)</p> <p>5. Co-director of the benign tumor service at MSKCC</p> <p>Serve as a primary faculty overseeing fellows, residents, medical students, and nurses at the Memorial Sloan Kettering Cancer Center for the treatment of brain tumors. Effort commitments: 70% research, 20% clinical, 9% teaching, administration 1%.</p> <p>Duties: Outpatient clinic – See new patients, follow-up and on-treatment patients. Cover inpatient consults related to urgent/emergent radiation oncology call service. Present cases and attend weekly multidisciplinary tumor boards (CNS, radiosurgery). Teach medical students and residents during clinic visits and radiation treatment planning. Oversee clinic nurse, house staff, and clinical administrative assistant. Co-Principal Investigator or Co-investigator of multiple clinical trials.</p> <p>Member of Research Council, MSKCC (2013-2015)</p>	
--	--

3. Research (duties, dates): Summarize research activities in the table below. Provide key contributions, and annotate key grants and publications or use a [Statement of Key Contributions](#). Refer to it here and attach it to the CV.

Laboratory-based research

Research Activity / Key Contributions	Dates
<p>Function of src family proto-oncogenes in Hydra development</p> <p>Role: Research assistant</p> <ul style="list-style-type: none"> Characterized tyrosine kinase signaling networks in simple metazoans; identified ZAP70 and other tyrosine kinases in Hydra and characterized evolutionary conservation of tyrosine kinase genes in multicellular organisms. <p>Papers published, see Bibliography (University of California Irvine; PI: Dr. Robert Steele)</p>	1989-1991
<p>Gene targeting using recombinant adenoviruses</p> <p>Role: Research assistant</p> <ul style="list-style-type: none"> Developed novel methods of gene targeting using adenovirus-based systems <p>(Indiana University; PI: Dr. Milton Taylor)</p>	1992 (summer)
<p>Analysis of the human liver extracellular ATPase</p> <p>Role: undergraduate research assistant</p> <ul style="list-style-type: none"> Characterized the function of extracellular ATPases in cell signalling and metabolism sensing <p>(Harvard University; PI: Dr. Guido Guidotti)</p>	1991-1992
<p>Cell cycle regulation of histone gene expression; post-translational regulation of TNF</p> <p>Role: Research fellowship (University of North Carolina, Chapel Hill; PI: Dr. William Marzluff)</p>	1993 (summer)
<p>Function of the cyclin-dependent kinase inhibitors p21 and p15</p>	1994 (summer)

<p>Role: Undergraduate research fellowship</p> <ul style="list-style-type: none"> Identified mutations of p15 and p16 in human cancers; characterized binding partners of cyclin-dependent kinase inhibitors <p>Papers published, see Bibliography (Cold Spring Harbor, NY; PI: Dr. David Beach)</p>	
<p>Molecular mechanisms of axon guidance</p> <p>Role: Undergraduate researcher, thesis lab</p> <ul style="list-style-type: none"> Delineated the role of neuronal guidance molecules using in situ laser inactivation of proteins <p>Papers published, see Bibliography (Harvard University; PI: Dr. Dan Jay)</p>	1993-1995
<p>Mechanisms of the p53-dependent G2 checkpoint; molecular basis of the chemopreventative properties of nonsteroidal anti-inflammatory drugs</p> <p>Role: graduate student, MD/PhD program (MSTP)</p> <ul style="list-style-type: none"> Worked out the mechanisms underlying G3 arrest by p53; developed novel approaches to engineer somatic cell genomes <p>Papers published in Nature, Cell, PNAS, Genes and Development, etc., see Bibliography (Johns Hopkins School of Medicine; PI: Bert Vogelstein)</p>	1996-2002
<p>Identification and characterization of novel tumor suppressors in breast and colon cancer using global analysis of mutation and hypermethylation</p> <p>Role: postdoc research fellow</p> <ul style="list-style-type: none"> Characterized convergence of genetic and epigenetic aberrations on cancer genes; epigenomics <p>Papers published in PLoS Medicine, PLoS Genetics, etc., see Bibliography (Johns Hopkins Cancer Center; PI: Stephen Baylin)</p>	2006-2007
<p>Molecular genetics of human cancers</p> <p>Role: PI and lab head, cancer genetics laboratory, Human Oncology and Pathogenesis Program (HOPP) (MSKCC)</p> <ul style="list-style-type: none"> Focus: Characterization of cancer genomes; unraveling the master regulators of complex cancer programs; elucidating the genetic determinants of response to immunotherapy We have developed novel methods to characterize cancer genomes. We worked out the mutational landscapes of several cancer and played a key role in a number of TCGA cancer genomics consortium studies. We mapped 4 new cancer genes that are among the most widely altered in human cancers. We helped work out how IDH mutation leads to tumorigenesis and reprograms the epigenome We are the first to show how the mutational landscape helps dictate response to immunotherapy. <p>Papers published in Nature, New England Journal of Medicine, Science, Cell, PNAS, Nature Genetics, Science Translational Medicine, etc.; see Bibliography (Memorial Sloan Kettering Cancer Center, NY)</p>	8/15/2007-present

Clinical Research

<p>09-166 Monitoring Brain Tumor Response to Radiation Using Sodium MR Imaging (PI: Michelle Bradbury)</p> <p>Phase I trial to determine efficacy of using next-generation Sodium MRI to evaluate treatment response in malignant glioma patients undergoing chemoradiation.</p>	Co-principal investigator
<p>97-059 Analysis of Existing Tumor Specimens for Somatic Genetic Alterations Associated with Cancer (PI: William Gerald)</p>	Co-investigator

09-177 Phase I Trial of RO4929097 in Combination with Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study (NCI #8556) (PI: Antonio Omuro)	Co-investigator
08-137 Phase I/II Study of Vandetanib with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (PI: Thomas Kaley)	Co-investigator
08-106 Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma (NABTC 07-01) (PI: Antonio Omuro)	Co-investigator
08-126 A Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients with Newly Diagnosed Malignant Glioma (PI: Antonio Omuro)	Co-investigator
04-061 A Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases (PI: Kathryn Beal)	Co-investigator
02-089 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients with Newly Diagnosed Anaplastic Oligodendroglioma (PI: Antonio Omuro)	Co-investigator
09-003 Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients with BRAF or NRAS Mutated Melanomas (NCI #8252) (PI: Paul Chapman)	Co-investigator

4. Administrative Activities (duties, dates): Describe administrative activities in the table below. To document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.

Administrative Activity	Date
Process Review Task Group, Department of Radiation Oncology, Johns Hopkins Hospital	2006-2007
Education Committee, Department of Radiation Oncology, Johns Hopkins Hospital	2006-2007
Education Committee, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center	2007-present
Post-graduate Admissions Committee, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center	2007-present
Scientific Review Committee, American Society for Therapeutic Radiology and Oncology (ASTRO)	2007- 2010
Faculty Advisor, Geoffrey Beene Translational Oncology Core, Memorial Sloan-Kettering Cancer Center	May 2009-present
Member, Disease Working Group, Colorectal Disease The Cancer Genome Atlas project (TCGA)	2010-2013
Member, Analysis Working Group, Colorectal Disease The Cancer Genome Atlas project (TCGA)	2010-2013
PI, TCGA Colorectal Cancer Group MSKCC	2010-2012
Scientific Advisory Board, Cancer Genetics, Inc. (New York)	2010-present
Member of MD/PhD Interview Committee (Cornell/MSKCC/Rockefeller Univ. Program)	2010-present
Geoffrey Beene Cancer Center Retreat Planning Committee	2010-2012
Brain Tumor Center Tissue Utilization Committee (MSKCC)	2011-present
Scientific Advisory Board, QuanDx, Inc. (New York)	2011-present
Brain Tumor Center Seminar Chair/Academic Coordinator	2011-2013
Tumor Procurement Service Quality Committee (MSKCC)	2012-present
Advisory Board, Dana Farber Physical Sciences Oncology Center	2012-present
Executive Committee, Center for Molecular Oncology, MSKCC	2012-present
Memorial Sloan Kettering Research Council	2013-2015

GSK graduate school scholarship committee	2013-present
Department of Radiation Oncology Cancer Biology Course co-director	2013
Mayo Clinic/Oncospire Institute of Personalized Medicine, Scientific Advisory Board	2013-present
Memorial Sloan Kettering Awards Committee	2013-present
Human Oncology and Pathogenesis Program Faculty Recruitment Committee	2014-present
Leadership Committee, CVC Trials Network	2014-present
Leadership Committee, Functional Genomics Initiative, MSKCC	2014-present
Thyroid SPOR Developmental Projects Program Review Committee	2014-present
Dept. of Radiation Oncology Faculty Recruitment Committee	2012-present
Member, Parker Institute for Immunotherapy (MSKCC)	2015-present
Genocea Inc., Advisory Board	2015-present
Illumina, Advisory Board	2016-present
Co-founder, Gritstone Oncology Company focused on developing immunotherapeutics	2015

H. **EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

i.e. - Journal Reviewer, Editorial Boards, Study Sections, Invited Presentations

Invited Lectures

Activity / Responsibility	Dates
The structure and function of tyrosine kinase proto-oncogenes in Hydra. (London, UK) The London Youth International Fortnight	1991
The structure and function of tyrosine kinase proto-oncogenes in Hydra. (Washington, DC) The National Junior Science and Humanities Symposium,	1991
The structure and function of tyrosine kinase proto-oncogenes in Hydra. (Washington, DC) The American Association for the Advancement of Science (AAAS)	1991
Tyrosine kinase proto-oncogenes in development (Los Angeles, CA) Southern California Academy of Science	1990
Post-transcriptional regulation of tumor necrosis factor (Chapel Hill, NC) University of North Carolina, Chapel Hill	1993
Axon guidance in neurons by neural cell adhesion molecule signaling pathways (Irvine, CA) University of California, Irvine Seminar	1994
Regional laser inactivation of L1 and N-CAM alters growth cone motility (San Diego, CA) Society for Neuroscience 24 th Annual Meeting	1995
Mechanisms of non-steroidal anti-inflammatory drug mediated apoptosis (New York, NY) IBC Conference on COX II Inhibitors	1998
Radiation-induced Genomic Instability (Rockville, VA) National Cancer Institute Annual Radiobiology Conference	1999
Dissection of the p53 and G2/M DNA damage checkpoints Japanese Cancer Association 59 th Annual Meeting 2000 (Yokohama, Japan) (symposium lecture)	2000

Using SAGE and human somatic cell genetics to investigate cell cycle checkpoint control Kyoto University Seminar, invited speaker 2000 (Kyoto, Japan)	2000
Colon Cancer Chemoprevention Gastrointestinal Society of Taiwan Annual Meeting (Taipei, Taiwan) (lecture, Plenary session)	2003
Annotating the Cancer Genome: Combined Genetic and Epigenetic Analysis of Breast and Colon Cancer Geoffrey Beene Cancer Biology Conference 2008 (PA)	2008
New Technologies for Colorectal Cancer Screening NCMA Conference, NY	2008
Analyzing the Breast Cancer Hypermethylome FAMRI Annual Conference (Boston, MA)	2008
Molecular Determinants of Response to Therapy American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting (Boston, MA) (chair, oral presentations session)	2008
Integrated Genomic Analysis Identifies PTPRD as a Broadly Inactivated Tumor Suppressor in Human Cancers Geoffrey Beene Cancer Biology Conference 2008 (PA)	2009
Annotating the Cancer Genome: Combined Genetic and Epigenetic Analysis State University of New York (Stony Brook, NY)	2009
DNA Damage and Repair American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting - Chair, Oral Presentations Session (Chicago, MA)	2009
High Grade Gliomas. Recent Advances in Biology and Treatment New York Roentgen Society (New York, NY)	2009
Astra Zeneca-MSKCC Science Day Invited Speaker (New York, NY)	2010
Identification of Clinically Significant Drivers of Oncogenesis Using Multifaceted Genomic Analysis Han-Mo Koo Memorial Seminar – Invited Speaker Van Andel Research Institute (Michigan)	2010
Finding Needles in the Haystack: Making Inroads into the Cancer Genome Major Trends in Modern Cancer Research, MSKCC (New York, NY)	2010
Tumor Profiling for Clinicians ASTRO Annual Meeting – Invited Lecture (San Diego, CA)	2010
Identification of Clinically Significant Drivers of Oncogenesis Using Multifaceted	2011

Genomic Analysis – Invited Speaker Stanford University (CA)	
PTPRD and the molecular pathogenesis of glioma Sontag Annual Research Meeting, Invited speaker (Jacksonville, FL)	2011
Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis American Association for Cancer Research Annual Meeting – Oral Presentation (Orlando, FL)	2011
Identification of Clinically Significant Drivers of Oncogenesis Using Multifaceted Genomic Analysis Georgia Health Sciences University – Invited Speaker Visiting Professor (GA)	2011
Making Inroads Into Cancer Genomes: Multifaceted Approaches to Cancer Gene Discovery Johns Hopkins School of Medicine – Oncology Center Biennial Conference Invited Speaker, Plenary Session (Baltimore, MD)	2011
Tumor Profiling for Clinicians ASTRO Annual Meeting – Invited Lecture, Educational Session (Miami, FL)	2011
Epigenomic bases for metastasis Dana Farber Cancer Center Physical Science Oncology Center Invited Lecture (NY)	2012
Drivers of Oncogenesis in Malignant Glioma Gerstner Sloan Kettering Graduate School Retreat Invited Lecture (NY)	2012
Drivers of Glioma Oncogenesis: Insights and Lessons Cancer Center Seminar Princess Margaret Cancer Center (Ontario, Canada)	2012
Epigenomic Drivers of Glioma Oncogenesis 11 th Annual International Neurooncology Conference Invited speaker (Baltimore, MD)	2012
Unraveling the Breast Cancer Metastasis Epigenome STARR Cancer Consortium Annual Meeting (Cold Spring Harbor, NY)	2012
IDH mutation and Epigenetic Reprogramming Sontag Research Annual Meeting Invited speaker (St. Johns, US Virgin Islands)	2013
Molecular Foundations of Glioma Dept. of Neurosurgery Grand Rounds Weill Cornell School of Medicine Invited Speaker (New York, NY)	2013
The Mutational Landscape of Adenoid Cystic Carcinoma Dana Farber Cancer Center Physical Science Oncology Center	2013

Harvard School of Medicine Invited Lecture (Boston, MA)	
Biomarkers for Distant Failure Derived From Analysis of the Breast Cancer Epigenome Avon Foundation Research Meeting Invited Lecture (New York, NY)	2013
Molecular Foundations of Glioma New York University School of Medicine Invited Speaker (New York, NY)	2013
Molecular Foundations of Glioma: Insights and Lessons University of Pennsylvania Abramson Family Cancer Research Institute Invited Speaker (Philadelphia, PA)	2013
Molecular Foundations of Adenoid Cystic Carcinoma International Myb Meeting University of New Mexico Invited Speaker (Albuquerque, NM)	2013
Molecular Foundations of Glioma: Insights and Lessons University of Washington Invited Speaker (Seattle, WA)	2013
Divers of Glioma: Insights and Lessons University of California, Irvine Invited Speaker (Irvine, CA)	2013
Molecular Foundations of Glioma: Insights and Lessons Mt. Sinai Hospital Invited Speaker (New York, NY)	2013
Cancer Genomics: Mechanisms and Insights University of Gothenberg Invited Speaker (Sweden)	2013
Dissecting and Targeting Actionable Drivers of Glioma Sontag Research Annual Meeting Invited Speaker Palm Springs, CA	2014
Novel Insights on Targeting Tough Cancers in the Age of Personalized Oncology Fred Hutchinson Cancer Research Center Invited Speaker Seattle, WA	2014
Genomic Portraits of Adenoid Cystic Carcinoma AACR 2014 – ACC Symposium Invited Speaker San Diego, CA	2014
Genomic Determinants of Clinical Response to Ipilimumab AACR 2014 – SU2C meeting Invited Speaker	2014

San Diego, CA	
The Genomics of Immune Checkpoint Blockade Commonwealth Research Summit Invited Speaker Baltimore, MD	2014
Tumor Exomes and Response to Immune Checkpoint Blockade Stand Up 2 Cancer Meeting Invited Speaker MD Anderson Cancer Center Houston, TX	2014
Cancer Genomics: Mechanisms and Insights National Swedish Cancer Research Annual Meeting 2014 Plenary lecture Karolinska Institute Stockholm, Sweden	2014
Scientific Session, Radiosensitizers – Discussant ASTRO Annual Meeting – Invited Talk (San Francisco, CA)	2014
Mutational Landscape and Response to Immune Checkpoint Inhibitors CVC Trials/22 nd Annual International Cancer Immunotherapy Symposium Cancer Research Institute Invited Lecture New York, NY	2014
Cancer Genomics: Mechanisms and Insights Case Western Reserve University – Invited lecture Cleveland, OH	2014
Cancer Genomics: Mechanisms and Insights New York Roentgen Society – Invited lecture New York City, NY	2014
Mutational Landscapes and Response to Immune Checkpoint Blockade International Immuno-Oncology Network (IION) Invited lecture New York City, NY	2015
Cancer Genomes and Immunotherapy Efficacy Melanoma Research Alliance (MRA) Invited lecture Washington, DC	2015
Cancer Genomics: Lessons and Insights Columbia University Oncology Grand Rounds New York, NY	2015
Cancer Genomes and Immunotherapy Efficacy Immunotherapy of Cancer Conference (ITOC) Plenary lecture Munich, Germany	2015
Cancer Genomics: Mechanisms of Oncogenesis University of Virginia Dept. of Neurology Grand Rounds Invited lecture Charlottesville, VA	2015
Mutational Profiling and Response to Immune Checkpoint Blockade Stand Up 2 Cancer Meeting Invited lecture Philadelphia, PA	2015

Mutational Landscape and Immunotherapy Efficacy AACR Annual Meeting Major Symposia, Invited lecture Philadelphia, PA	2015
Mutational Landscape and Immunotherapy Efficacy Irving Cancer Center Annual Symposium Invited lecture Columbia University, New York, NY	2015
Molecular Foundations of IDH Mutant Glioma AACR Advances in Brain Tumor Research Plenary lecture Washington D.C.	2015
Mutational Landscape and Immunotherapy Efficacy AACR Precision Medicine Invited lecture – Major lecture Salt Lake City, Utah	2015
Mutational Landscape and Immunotherapy Efficacy Nature Conference – Immunity in Health and Disease Invited lecture Seattle, WA	2015
Genomic Landscapes and Immune Checkpoint Blockade Japanese Cancer Association Annual Meeting Invited Lecture Nagoya, Japan	2015
Mutational Landscape and Immunotherapy Efficacy SITC (Society for Immunotherapy of Cancer) Invited lecture National Harbor, Maryland	2015
Genomic Landscapes and Immunotherapy Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy Invited lecture Tokyo, Japan	2015
Genomic Applications for Immunotherapy New York Genome Center Invited lecture New York, NY	2016
Cancer Genomics: Lessons and Insights Neurosciences Grand Rounds Yale University Invited lecture New Haven, CT	2016
Immunotherapy: What's Genes Got To Do With It? Yale Cancer Center Radiobiology and Radiotherapy Retreat Keynote lecture Yale University New Haven, CT	2016
Immunotherapy: What's Genes Got To Do With It? Molecular Pathology lecture series Invited lecture Johns Hopkins School of Medicine Baltimore, MD	

I. PROFESSIONAL MEMBERSHIPS

Include medical and scientific societies.

Member/Officer/Fellow/Role	Organization	Dates
Member	American Society of Therapeutic Radiology and Oncology (ASTRO)	2002-present
Member	American Society of Clinical Oncology (ASCO)	2006-present
Member	American Association for Cancer Research (AACR)	May 2008-present
Member	American College of Radiology (ACR)	2009-present
Member	American Society of Clinical Investigation (ASCI)	2013-present

J. HONORS AND AWARDS

Name of award	Date awarded
National Junior Science and Humanities winner (1 st place)	1991
Ford Program Undergraduate Research Grant	1993
Barry Goldwater National Science Prize	1994
Phi Beta Kappa	1995
NIH Medical Scientist Training Program \$330,000 (full medical school tuition + stipend support 7 years)	September 1995-June 2002
Paul Erlich Prize: Awarded for excellence in research at Johns Hopkins Medical School	2001
Johns Hopkins Fellows Research Award: For outstanding research	2002
ASTRO Young Investigator Travel Award	2005
ASTRO Translational Research Travel Award	2005
ASTRO Award of Merit: for outstanding research	2005
American Society of Clinical Oncology: Young Investigator Award	July 2007
Louis Gerstner Investigator Award	December 2008
FAMRI Scholar Award	July 2008
Doris Duke Clinical Scientist Development Award	June 2009
Han-Mo Koo Memorial Lectureship Award Van Andel Research Institute, MI	2010
Sontag Distinguished Scientist Award	2010
DOD Era of Hope Scholar	2012
American Society of Clinical Investigation (ASCI) membership	2013
Incumbent of the Frederick R. Adler Chair	December 2012 – present
Sahlgrenska Distinguished Lectureship (Sweden)	December 2013
Pershing Square Sohn Cancer Research Award	2015

K. BIBLIOGRAPHY

a. Articles in professional peer-reviewed journals

1. **Chan T**. Structure and function of *Hydra* tyrosine kinase proto-oncogenes. ***BASE*** 1992.
2. **Chan TA**, Chu CA, Rauen KA, Kroihner M, Tatarewicz SM, Steele RE. Identification of a gene encoding a novel protein-tyrosine kinase containing SH2 domains and ankyrin-like repeats. ***Oncogene*** 1994. PMID: 8134129.
3. Suzuki H, Zhou X, Yin J, Lei J, Jiang HY, Suzuki Y, **Chan T**, Hannon GJ, Mergner WJ, Abraham JM, Meltzer SJ. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. ***Human Molecular Genetics*** 1995. PMID: 8595411.
4. DaCosta LT, Jen J, He T, **Chan TA**, Kinzler KW, Vogelstein B (1996) Converting cancer genes into killer genes. ***Proceedings of the National Academy of Sciences USA*** 1996. PMID: 8633039. PMCID: PMC39510.
5. Zhou X, Suzuki H, Lei J, Cole K, Yin J, Suzuki Y, Abraham JM, Shimada Y, Imamura M, **Chan T**, Hannon GJ, Meltzer SJ (1996) Growth Suppression of Esophageal Cancer Cells by p16^{INK4} and p15^{INK4B} in vitro. ***Cancer J Sci Am*** 1996. PMID: 9166536.
6. **Chan TA**, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. ***Proceedings of the National Academy of Sciences USA*** 1998. PMID: 9435252. PMCID: 18480.
7. **Chan TA**, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3 σ is required to prevent mitotic catastrophe after DNA damage. ***Nature*** 1999. (featured article in News & Views) PMID: 10524633.
8. He T, **Chan TA**, Vogelstein B, Kinzler KW. PPAR δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. ***Cell*** 1999. PMID: 10555149. PMCID: PMC3779681.
9. Takei K, **Chan TA**, Wang F, Deng H, Rutishauser U, Jay DG. The neural cell adhesion molecules L1 and NCAM-180 act in different steps of neurite outgrowth. ***The Journal of Neuroscience*** 1999. PMID: 10531450.
10. Ferguson AT, Evron E, Umbricht CB, Pandita TK, **Chan TA**, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. ***Proceedings of the National Academy of Sciences USA*** 2000. PMID: 10811911 PMCID: PMC18556.
11. **Chan TA**, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B. Cooperative effects of genes controlling the G(2)/M checkpoint. ***Genes and Development*** 2000. PMID: 10887152. PMCID: PMC316737.
12. Hwang PM, Bunz F, Yu J, Rago C, **Chan TA**, Murphy MP, Kelso GF, Smith RAJ, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. ***Nature Medicine*** 2001. PMID: 11590433. PMCID: PMC4086305.
13. **Chan TA**, Wang Z, Dang LH, Vogelstein B, Kinzler KW. Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. ***Proceedings of the National Academy of Sciences USA*** 2002. PMID: 12060769. PMCID: PMC123056.
14. **Chan TA**. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. ***Curr Cancer Drug Targets*** 2003. PMID: 14683503.
15. **Chan TA**, Weingart JD, Parisi M, Hughes MH, Olivi A, Borzillary S, Alahakone D, Detorie NA, Wharam MD, Kleinberg L. Treatment of recurrent glioblastoma multiforme with GliSite brachytherapy. ***International Journal of Radiation Oncology, Biology, Physics*** 2005. PMID: 15990019.
16. Gerber DE, Grossman SA, **Chan TA**, Kleinberg LE. Intracranial hemorrhage during GliSite RTS manipulation in an anticoagulated patient. ***Journal of Radiation Oncology in Practice*** 2007. PMID: 19173012. PMCID: PMC2630704.
17. Schuebel KE, Chen WE, Cope L, Glockner S, Suzuki H, Yi J, **Chan TA**, Van Neste L, Van Criekinge W, *et al.* Comparing the DNA hypermethalome with gene mutations in human colorectal cancer. ***PLoS Genetics*** 2007. PMID: 17892325. PMCID: PMC1988850.
18. **Chan TA**, Glockner S, Yi JM, Chen W, Van Neste L, Cope L, Herman JG, Velculescu V, Schuebel KE, Ahuja N, Baylin SB. Convergence of mutation and epigenetic alterations identifies

- common genes in cancer that predict for poor prognosis. *PLoS Medicine* 2008. PMID: 18507500. PMCID: PMC2429944.
19. Wong J, Armour E, Kazandies P, Iordachita I, Tryggestad E, Deng H, Matinfar M, Kennedy C, Liu Z, **Chan T**, Gray O, Verhaegen F, McNutt T, Ford E, DeWeese TL. High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. *International Journal of Radiation Oncology, Biology, Physics* 2008. PMID: 18640502. PMCID: PMC2605655.
 20. Glockner SC, Yi JM, McGarvey KE, Van Neste L, Van Engeland M, **Chan TA**, Kleeberger W, Dhir M, de Bruine AP, Khalid C, Stockbrugger RW, Meijer GA, Oort F, Iacobuzio-Donahue C, Herman JG, Baylin SB, Schuebel KE, Ahuja N. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. *Cancer Research* 2009. PMID: 19435926. PMCID: PMC3062162.
 21. Veeriah S, Brennan C, Meng S, Fang F, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liao L, Cloughesy TC, Mischel PS, Sander C, Taylor B, Schultz N, Major J, Heguy A, Mellinghoff IK, **Chan TA***. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. *Proceedings of the National Academy of Sciences USA* 2009. *Corresponding author. PMID: 19478061. PMCID: PMC2687998.
 22. Meng S, Arbit T, Veeriah S, Mellinghoff IK, Rohle D, Vivanco I, **Chan TA***. 14-3-3 σ and p21 synergize to determine DNA damage response following Chk2 inhibition. *Cell Cycle* 2009. *Corresponding author. PMID: 19502805.
 23. **Chan TA***, Heguy A. The protein tyrosine receptor phosphatase D, a broadly inactivated tumor suppressor regulating STAT function. *Cell Cycle* 2009. *Corresponding author. PMID: 19755842.
 24. Kleinberg L, Yoon G, Weingart J, Olivi A, **Chan TA***. Imaging after GliSite brachytherapy: prognostic MRI indicators of disease control and recurrence. *International Journal Of Radiation Oncology, Biology, Physics* 2009. *Corresponding author. PMID: 19394153.
 25. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liao L, Cloughesy TF, Mellinghoff IK, Solit DB, **Chan TA***. Somatic mutations of the Parkinson's disease-associated gene *PARK2* in glioblastoma and other human malignancies. *Nature Genetics* 2010. *Corresponding author. PMID: 19946270. PMCID: PMC4002225.
 26. Veeriah S, Morris L, Solit D, **Chan TA***. The familial Parkinson disease gene *PARK2* is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. *Cell Cycle* 2010. *Corresponding author. PMID: 20372088. PMCID: PMC2921461.
 27. López-Lago MA, Thodima VJ, Guttapalli A, **Chan TA**, Heguy A, Molina AM, Reuter VE, Motzer RJ, Chaganti RSK. Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression. *Cancer Research* 2010. PMID: 20952505.
 28. Png KJ, Yoshida M, Zhang XHF, Shu W, Lee H, Rimner A, **Chan TA**, Comen E, Andrade V, Kim SW, King TA, Hudis C, Norton L, Hicks J, Massague J, Tavazoie SF. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. *Genes and Development* 2011. PMID: 21289068. PMCID: PMC3034897.
 29. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LGT, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, **Chan TA***. Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. *Science Translational Medicine* 2011. *Corresponding author. PMID: 21430268. PMCID: PMC3146366.
 30. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, **Chan TA**, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. *Journal of Thoracic Oncology* 2011. PMID: 22089116.
 31. Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan C, Kaufman A, Kasthuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Jason Huse J, Ian Ganly I, **Chan TA***. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals

- frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. **Proceedings of the National Academy of Sciences** 2011. *Corresponding author. PMID: 22065749. PMCID: PMC3223475.
32. Morris LG, **Chan TA***. Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancer. **Oncotarget** 2011. PMID: 22248868. PMCID: PMC3282094.
 33. Siu A, Wind JJ, Iorgulescu JB, **Chan TA**, Yamada Y, Sherman JH. Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding. **Acta Neurochirurgica** 2012. PMID: 22130634.
 34. Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AW, **Chan TA**, Stallings RL. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. **Mol Cancer** 2012. PMID: 22305495. PMCID: PMC3395855.
 35. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, **Chan TA**, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. **Clin Cancer Res** 2012. PMID: 22228633.
 36. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward F, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, **Chan TA***. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. **Nature** 2012. *Corresponding author. PMID: 22343889. PMCID: PMC335169
 37. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards C, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, **Chan TA**, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. **Nature** 2012. PMID: 22343901. NIHMSID: 400580.
 38. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, **Chan TA**, Huse JT. IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma. **Clin Cancer Res** 2012. PMID: 22415316.
 39. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, **Chan TA**, Saltz LB, Weiser M, Solit DB. Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. **Journal of Clinical Oncology** 2012. PMID: 22665543. PMCID: PMC3417049.
 40. The Cancer Genome Atlas Network (TCGA) (**Timothy A. Chan** – member, analysis working group; member of leadership writing manuscript on behalf of the entire TCGA) Comprehensive molecular characterization of human colon and rectal cancer. **Nature** 2012. PMID: 22810696. PMCID: PMC3401966
 41. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, **Chan TA**, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. **Epigenetics** 2012. PMID: 22647880.
 42. Young RJ, Gupta A, Shah AD, Graber JJ, **Chan TA**, Zhang A, Shi W, Beal K, Omuro AM. MRI perfusion in determining pseudoprogression in patients with glioblastoma. **Clinical Imaging** 2012. PMID: 23151413.
 43. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, Pirun M, Sander C, Succi ND, Ostrovnya I, Viale A, Heguy A, Peng L, **Chan TA**, Bochner B, Bajorin DF, Berger MF, Taylor BS, Solit DB. Genome sequencing identifies a basis for everolimus sensitivity. **Science** 2012. PMID: 22923433. PMCID: PMC3633467.
 44. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kasterhuber ER, Heguy A, Petrini JH, **Chan TA**, Huse JT. Whole exome sequencing identified ATRX mutation as a key molecular determinant in lower grade glioma. **Oncotarget** 2012. PMID: 23104868. PMCID: PMC3717947.
 45. Reyngold M, Lassman AB, **Chan TA**, Yamada Y, Gutin PH, Beal K. Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. **J Neurooncology** 2012. PMID: 22983908.

46. Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts N, Bhan S, Ho A, Khan Z, Bishop J, Westra W, Tufano R, Robinson B, Dralle H, Toledo S, Toledo R, **Chan TA**, Ghossein RA, Fagin JA, Velculescu V, Vogelstein B, Kinzler K, Papadopoulos N, Nelkin B, Ball D. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in *RET* and *RAS*. **J Clin Endocrinology and Metabolism** 2012. PMID: 23264394. PMCID: PMC3565108.
47. Omuro A, **Chan TA**, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. **Neuro Oncol** 2013. PMID: 23243055. PMCID: PMC3548585.
48. Morris LGT, Kaufman AM, Gong Y, Ramaswami R, Walsh LA, Turcan S, Eng S, Kannan K, Zou Y, Peng L, Banuchi VE, Paty P, Zeng Z, Vakiani E, Solit D, Singh B, Ganly G, Liao L, Cloughesy TC, Mischel PS, Mellinghoff IM, **Chan TA***. Recurrent somatic mutation of *FAT1* in multiple human cancers leads to aberrant Wnt activation. **Nature Genetics** 2013. *Corresponding author. PMID: 23354438. PMCID: PMC3729040.
49. Morris LGT, Ramaswami D, and **Chan TA***. The *FAT* epidemic: a gene family frequently mutated across multiple human cancer types. **Cell Cycle** 2013. *Corresponding author. PMID: 23493187. PMCID: PMC3646852.
50. Barker CA, Bishop AJ, Chang M, Beal K, **Chan TA**. Valproic acid use during radiotherapy for glioblastoma associated with improved survival. **International Journal of Radiation Oncology, Biology, Physics** 2013. PMID: 23523186.
51. Ganly I, Filho JR, Eng S, Ghossein R, Morris LGT, Liang Y, Socci N, Kannan K, Mo Qianxing, Fagin JA, and **Chan TA***. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. **J Clin Endocrinology and Metabolism** 2013. *Corresponding author. PMID: 23543667.
52. Rohle D*, Popovici-Muller J*, Palaskas N*, Turcan S*, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, **Chan TA**, Graeber TG, Yen KE, and Mellinghoff IK. A novel inhibitor of mutant isocitrate dehydrogenase 1 (*IDH1*) delays growth and promotes differentiation in *IDH1* mutant glioma cells. **Science** 2013. *Equal contribution. PMID: 23558169. PMCID: PMC3985613.
53. Ho AS, Kannan K, Roy DM, Morris LGT, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng, Stephanie, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, and **Chan TA***. The Mutational Landscape of Adenoid Cystic Carcinoma. **Nature Genetics** 2013. *Corresponding author. PMID: 23685749. PMCID: PMC3708595.
54. Tonjes M, Barbus, S, Yoon, JP, Wang W, Schlotter M, Lindroth AM, Pleier SV, Bai AH, Karra D, Piro RM, Felsberg J, Addington A, Lemke D, Weibrecht I, Hovestadt V, Rolli CG, Campos B, Turcan S, Strum D, Witt H, **Chan TA**, Herold-Mende C, Kemkemer R, Konig R, Schmidt K, Hull WE, Pfister S, Jugold M, Hutson SM, Plass C, Okun JG, Reifenberger, Lichter P, Radlwimmer B. *BCAT1* promotes cell proliferation through amino acid catabolism in gliomas carrying wild type *IDH1*. **Nature Medicine** 2013. PMID: 23793099.
55. Landa I, Ganly I, **Chan TA**, Mitsutake N, Matsuse M, Ibrahimasic T, Ghossein RA, and Fagin, JA. Frequent somatic *TERT* promoter mutations in thyroid cancer: Higher prevalence in advanced forms of the disease. **J Clin Endocrinology and Metabolism** 2013. PMID: 23833040. PMCID: PMC3763971.
56. Booth D, Young R, Yamada Y, Prager A, **Chan T**, Beal K. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. **Neuro-Oncology** 2013. PMID: 23814264. PMCID: PMC3748921.
57. Borodovsky A, Salmasi V, Turcan S, Fabius AWM, Baia GS, Eberhart CG, Weingart JD, Gallia GL, Baylin SB, **Chan TA**, Riggins GJ. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived *IDH1* mutant glioma xenograft.

- Oncotarget** 2013. PMID: 24077805. PMCID: PMC3858560.
58. Turcan S, Fabius AWM, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, and **Chan TA***. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. **Oncotarget** 2013. *Corresponding author. PMID: 24077826. PMCID: PMC3858559.
 59. Spratt DE, Folkert M, Zumsteg ZS, **Chan TA**, Beal K, Gutin PH, Pentsova E, Yamada Y. Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma. **J Neurooncology** 2013. PMID: 24190580.
 60. Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y, **Chan TA**, Lymberis SC, Narayana A, Tabar T, Gutin PH, Ballangrud A, Lis E, Beal K. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. **International Journal of Radiation Oncology, Biology, Physics** 2014. PMID: 24331659.
 61. Leder K, Pitter K, LaPlante Q, Hambardzumyan D, Ross BD, **Chan TA**, Holland EC, Michor F. Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. **Cell** 2014. PMID: 24485463. PMCID: PMC3923371.
 62. Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat L, **Chan TA***. Remodeling of the methylation landscape in breast cancer metastasis. **PLoS One** 2014. *Corresponding author. PMID: 25083786. PMCID: PMC4118917.
 63. Ung N, Putoczki TL, Stylii S, Ng I, Mariadason JM, **Chan TA**, Zhu HJ, and Luwor RB. Anti-EGFR therapeutic efficacy correlates directly with inhibition of Stat3 activity. **Cancer Biology and Therapy** 2014. PMID: 24556630. PMCID: PMC4026085.
 64. Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, and **Chan TA***. Transcriptional diversity of long-term glioblastoma survivors. **Neuro-Oncology** 2014. *Corresponding author. PMID: 24662514. PMCID: PMC4136896.
 65. Gerber NK, Yamada Y, Rimner A, Shi W, Riely GJ, Beal K, Yu H, **Chan TA**, Zhang Z, and Wu AJ. Erlotinib versus radiation therapy for brain metastases in patients with lung adenocarcinoma and EGFR mutations. **International Journal of Radiation Oncology, Biology, Physics** 2014. PMID: 24679729.
 66. Gong Y, Zack TI, Morris LGT, Lin K, Hukkelhoven E, Raheja R, Veeriah S, Meng S, Viale A, Schumacher SE, Beroukhir R, and **Chan TA***. Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. **Nature Genetics** 2014. *Corresponding author. PMID: 24793136. PMCID: PMC4251771. (featured in News and Views)
 67. Ortiz B, Fabius AWM, Wu W, Pedraza A, Brennan C, Schultz N, Pitter KL, Bromberg J, Huse JT, Holland EC, and **Chan TA***. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. **Proceedings of the National Academy of Sciences** 2014. *Corresponding author. PMID: 24843164. PMCID: PMC4050622.
 68. Walsh LA, Roy DM, Reyngold M, Giri D, Snyder A, Turcan S, Badwe CR, Lyman JL, Bromberg J, King TA, and **Chan TA***. RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. **Oncogene** 2014. *Corresponding author. PMID: 24931164. PMCID: PMC4344427.
 69. Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, Drobnjak M, Vahdat LT, Lee W, **Chan TA**. Remodeling of the methylation landscape in breast cancer metastasis. **PLoS One** 2014 Aug 1. PMID: 25083786. PMCID: PMC4118917.
 70. Omuro AM, Beal K, Gutin G, Karimi S, Correa D, Kaley TJ, DeAngelis LM, **Chan TA**, Gavrilovic IT, Nolan C, HOrnigo A, Lassman AB, Mellingshoff IK, Grommes C, Reiner AS, Panageas K, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan C, Abrey L, Huse JT. Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. **Clin Cancer Research** 2014. PMID: 25107913.
 71. Ortiz B, White JR, Wu WH, and **Chan TA***. Deletion of Ptpd and Cdkn2a cooperate to accelerate tumorigenesis. **Oncotarget** 2014 Jun 14. *Corresponding author. PMID: 25138050. PMCID: PMC4196177.
 72. Yang TJ, Oh JH, Folkert MR, Gupta G, Shi W, Zhang Z, Morikawa A, Seidman A, Brennan C,

- Yamada Y, **Chan TA**, and Beal K. Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. *International Journal of Radiation Oncology, Biology, Physics* 2014. PMID: 25194669.
73. Gerber N, Young RJ, Barker CA, Wolchok JD, **Chan TA**, Yamada Y, and Beal K. Ipilimumab and whole brain radiation therapy in melanoma brain metastases. *J Neurooncology* 2014 Oct 2. [Epub ahead print]. PMID: 25273687.
74. Barker C, Chang M, Beal K, and **Chan TA**. Survival of patients treated with radiation therapy for anaplastic astrocytoma. *Radiology and Oncology* 2014. PMID: 25435851. PMCID: PMC4230558.
75. Gong Y and **Chan TA***. Molecular mechanisms orchestrating cyclin stability. *Cell Cycle* 2014. *Corresponding author. PMID: 25486187.
76. The Cancer Genome Atlas Network (TCGA) (**Timothy A. Chan** co-author) Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014. PMID: 25417114. PMCID: PMC4243044.
77. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TA, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli E, Liu C, Harbison CT, Wang L, Ribas A, Wolchok, JD, and **Chan TA***. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *The New England Journal of Medicine* 2014. *Corresponding author. PMID: 25409260. PMCID: PMC4315319. (featured in accompanying Editorial)
78. Wolchok JD and **Chan TA**. Cancer: Antitumour immunity gets a boost. *Nature* 2014. PMID: 25428495.
79. The Cancer Genome Atlas Network (TCGA) (**Timothy A. Chan** co-author) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015. PMID: 25631445. PMCID: PMC4311405.
80. Snyder A, Wolchok, JD, and **Chan TA***. Basis of Clinical Response to Ipilimumab – correspondence to the Editor. *New England Journal of Medicine* 2015. *Corresponding author. PMID: 25693024.
81. Keiss AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, **Chan TA**, Yamada Y, Beal, K. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. *International Journal of Radiation Oncology, Biology, Physics* 2015. PMID: 25754629.
82. Rizvi N, Hellmann MD, Snyder A, Kvistborg P, Makarov M, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, and **Chan TA***. Mutational landscape determines sensitivity to programmed cell death-1 blockade in non-small cell lung cancer. *Science* 2015 March 12. PMID: 25765070. *Corresponding author.
83. Havel JJ and **Chan TA***. High-resolution genomic analysis: the tumor-immune interface comes into focus. *Genome Biology* 2015. *Corresponding author. PMID: 25853850. PMCID: 4377855
84. The Cancer Genome Atlas Network (TCGA) (**Timothy A. Chan** co-author) Comprehensive, integrative genomic analysis of diffuse lower grade gliomas. *New England Journal of Medicine* 2015. PMID:26061751 PMCID4530011
85. Hellmann M, Rizvi N, Wolchok JD, and **Chan TA***. Genome Profiles, smoking, and response to anti-PD-1 therapy in non-small cell lung cancer. *Mol Cell Oncology* 2015. *Corresponding author. (in press)
86. Chiappinelli KB#, Strissel P#, Desrichard A#, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Mergoub T*#, **Chan TA*#**, Baylin SB*#, and Strick R*#. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell* 2015. PMID: 26317466. PMCID4556003
#contributed equally
*co-senior author
87. Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrtta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, **Chan TA**, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B. Genomic landscape

- of adenoid cystic carcinoma of the breast. *J Path* 2015. PMID: 26095796
88. Li G, Ballangrud A, Chan M, Ma R, Beal K, Yamada Y, **Chan T**, Lee J, Parhar P, Mechalakos J, and Hunt M. Clinical experience with two frameless stereotactic radiosurgery (SRS) systems using optical surface imaging for motion monitoring. *J Applied Clin Med Physics* 2015 16(4).
 89. Peyser ND, Du Y, Li H, Lui V, Xiao X, **Chan TA**, Grandis JR. Loss-of-function PTPRD mutations lead to increased STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. *Plos One* 2015. PMID: 26267899. PMCID4534317
 90. Cancer Genome Atlas Network (TCGA) (**Timothy A. Chan** co-author) Characterization of HPV and host genome interactions in primary head and neck cancers. *Proceedings of the National Academy of Sciences USA* 2015. PMID: 25313082.PMCID4217452
 91. Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S, Simon M, Krischek B, Ozduman K, Omay SB, Sorenson EA, Turcan S, Bakirciglu M, Carrion-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Altinok S, Kaulen LD, Gulez B, Timmer M, Chramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, **Chan TA**, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, and Gunel M. Integrated genomic characterization of IDH1 mutant glioma malignant progression. *Nature Genetics* 2015. Nov. 30. PMID: 26618343.
 92. Goh G, Walradt T, Makarov V, Blom A, Riaz N, Doumani R, Stafstrom K, Moshiri A, Yelistratova L, Levinsohn J, **Chan TA**, Nghiem P, Lifton RP, and Choi J. Mutational landscape of MCPyV-positive and MCPyV-negative merkel cell carcinomas with implications for immunotherapy. *Oncotarget* 2015. PMID: 26655088.
 93. Wolchok JD and **Chan TA**. Central dogma for immunotherapy. In Voices. Immunotherapy: The path to win the war on cancer? *Cell* 2015. PMID: 26042237
 94. He Q, Kong L, Wang Y, Wang S, **Chan TA**, Holland, E. Regularized quantile regression under heterogeneous sparsity with application to quantitative genetic traits. *Computational Statistics and Data Analysis* 2016. 95:222-239.
 95. Morris L*, Riaz N, Desrichard A, Senbabaoglu Y, Hakimi A, Makarov V, Reir-Filho J, and **Chan TA***. Pan-cancer analysis of intratumoral heterogeneity as a prognostic determinant of survival. *Oncotarget* 2016. PMID: 26840267.
*Corresponding authors.
 96. Gee HY, Sadowski CE, Aggarwal PK, Porath JD, Yakulov T, Schueler M, Lovric S, Ashraf S, Braun DA, Halbritter J, Fang H, Airik R, Vega-Warner V, Cho KJ, **Chan TA**, Morris LGT, French-Constant C, Allen ND, McNiell H, Buescher R, Kyrieleis H, Wallot M, Gaspert A, Kistler T, Milford DV, Saleem M, Keng WT, Alexander SI, Valentini RP, Licht C, Teh JC, Bogdanovic R, Koziell A, Bierzynska A, Soliman N, Otto E, Lifton R, Holzman L, Sibinga NE, Walz G, and Tufro A. FAT1 mutations cause glomerulotubular nephropathy. *Nature Communications* 2016. PMID: 26905694.
 97. Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell S, Donnola S, Dai C, Ozawa T, Chang M, **Chan TA**, Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D. Corticosteroids compromise survival in glioblastoma. *Brain* 2016. PMID: 27020328.
 98. Roy DL, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, and **Chan TA***. Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations. *Cancer Cell* 2016. PMID: 27165745.
*Corresponding author.
 99. McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birnbak NJ, Hiley CT, Watkins TBK, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, **Chan TA**, Hadrup SR, Quesada SA, Swanton C. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. *Science* 2016. PMID: 26940869.
 100. Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, Wang Q, Armenia J, West L, Dogan S, Wang L, Ramaswami D, Ho AL, Ganly I, Solit DB, Berger MF, Schultz N, Reis-

Filho JS, **Chan TA***, and Morris LGT*. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. **Clinical Cancer Research** 2016. PMID: 27103403.

*Corresponding authors.

101. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, **Chan T**, Okada H, Lotze M, Grandi P, Amankulor N. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. **Neuro-Oncology** 2016. PMID: 27116977.
102. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms LA, Peck KK, Gutin P, Iorgulescu JB, Kaley TJ, DeAngelis LM, Pentsova E, Nolan C, Grommes C, **Chan TA**, Bobrow D, Hormigo A, Cross JR, Wu N, Takebe N, Panageas K, Ivy SP, Supko JG, Tabar V, Omuro AM. Molecular and clinical effects of Notch inhibition in glioma patients: A phase 0/1 trial. **Clinical Cancer Research** 2016. PMID: 27154916.

L. Reviews

1. **Chan TA***. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon cancer chemoprevention. **Lancet Oncology** 2002. *Corresponding author. PMID: 11902503
2. **Chan TA***. Prostaglandins and the Colon Cancer Connection. **Trends in Molecular Medicine** 2006 Jun; 12(6): 240-244. *Corresponding author. PMID: 16650804.
3. Gerber D, **Chan TA**. Recent Advances in Radiation Therapy. **American Family Physician** 2008. (featured cover article). PMID: 19069018.
4. Morris L, Veeriah S, **Chan TA***. Genetic determinants at the interface of cancer and neurodegenerative disease. **Oncogene** 2010. *Corresponding author. PMID: 20418918. PMCID: PMC3005561.
5. **Chan TA***, Baylin SB. Epigenetic Biomarkers. **Current Topics in Microbiology and Immunology** 2011. *Corresponding author. PMID: 21818705.
6. Ho AS, Turcan S, **Chan TA***. Epigenetic therapy – use of agents targeting deacetylation and methylation in cancer management. **Oncotargets and Therapy** 2013. *Corresponding author. PMID: 23569385. PMCID: PMC3615839.
7. Turcan S and **Chan TA***. Mapping the genomic landscapes of pediatric low grade gliomas. **Nature Genetics** 2013. *Corresponding author. PMID: 23892663.
8. Roy DM, Walsh LA, and **Chan TA***. Driver mutations of cancer epigenomes. **Protein and Cell** 2014. *Corresponding author. PMID: 24622842. PMCID: PMC3978161
9. Riaz N, Morris G, Lee W, **Chan TA***. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. **Genes and Diseases** 2014. *Corresponding author. PMID: 25642447. PMCID: PMC4310010.
10. Morris LG* and **Chan TA***. Therapeutic targeting of tumor suppressors. **Cancer** 2014. *Corresponding author. PMID: 25557041.
11. Snyder A and **Chan TA***. Immunogenic peptide discovery in cancer genomes. **Current Opinions in Genetics and Development** 2015. *Corresponding author. PMID: 25588790.
12. Snyder A, Makarov V, Hellmann M, Rizvi N, Mergoub T, Wolchok JD, **Chan TA***. Genetics and Immunology: Reinvigorated. **Oncolmunology** 2015. *Corresponding author. PMID: 26451299. PMCID: PMC4589040
13. Desrichard A, Snyder A, **Chan TA***. Cancer neoantigens and applications for immunotherapy. **Clinical Cancer Research** 2015. PMID: 26515495. *Corresponding author.
14. Rizvi N and **Chan TA***. Immunotherapy and oncogenic pathways: The PTEN connection. **Cancer Discovery** 2016. PMID: 26851183. *Corresponding author.
15. Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, **Chan TA***. The role of neoantigens in response to immune checkpoint blockade. **International Immunology** 2016. PMID: 27048318. *Corresponding author.
16. Mandal R and **Chan TA***. Personalized oncology meets immunology: the path toward precision immunotherapy. **Cancer Discovery** 2016. PMID: 27107038. *Corresponding author.

Editorial, Ad Hoc Reviewer, and Study Sections

Editorial

Cancer Research, Editorial Board
Frontiers in Oncology, Editorial Board
Genes and Diseases, Editorial Board

Ad Hoc Reviewer

Reviewer, *Nature*
Reviewer, *Cell*
Reviewer, *New England Journal of Medicine*
Reviewer, *Nature Genetics*
Reviewer, *Nature Medicine*
Reviewer, *Cancer Cell*
Reviewer, *Proceedings of the National Academy of Sciences, USA*
Reviewer, *Journal of Clinical Oncology*
Reviewer, *Journal of Clinical Investigation*
Reviewer, *Science Translational Medicine*
Reviewer, *Cancer Discovery*
Reviewer, *The Lancet*
Reviewer, *International Journal of Radiation Oncology, Biology, Physics*
Reviewer, *Genome Biology*
Reviewer, *Neoplasia*
Reviewer, *PLoS One*
Reviewer, *Cancer*
Reviewer, *Cancer Research*
Reviewer, *Journal of Clinical Investigation*
Reviewer, *Expert Reviews*
Reviewer, *Journal of Pathology*
Reviewer, *Molecular Cancer Research*
Reviewer, *Acta Neuropathologica*
Reviewer, *Neurosurgery*
Reviewer, *PLoS Genetics*
Reviewer, *Molecular and Cellular Biochemistry*
Reviewer, *Clinical Cancer Research*
Reviewer, *Genome Medicine*
Reviewer, *Cell Cycle*
Reviewer, *FEBS Letters*
Reviewer, *Nature Biotechnology*
Reviewer, *Nature Communications*
Reviewer, *Neuro-Oncology*
Reviewer, *Molecular Oncology*
Reviewer, *Cancer Letters*
Reviewer, *Genes and Cancer*
Reviewer, *Journal of Thoracic Oncology*
Reviewer, *Oncology*

Study Sections and Grant Review

Grant Review Study Section, NIH, NIDCR Oral Cancers
Grant Review Study Section, NIH, Cancer Molecular Pathobiology (CAMP)
Grant Review Study Section, NIH, ZRG1 FO9-P(20), (F31/F32)
Grant Review Study Section, Department of Defense
Integration Panel, Department of Defense, CDMRP, Breast Cancer Program

Programmatic Review, Department of Defense, CDMRP, Breast Cancer Program
Grant Reviewer, Lustgarten Foundation
Grant Reviewer, Cancer Research UK
Grant Reviewer, Clinical and Translational Science Center
Grant Reviewer, FAMRI
Grant Reviewer, Association for International Cancer Research
Grant Reviewer, Genome Canada

b. Books, book chapters

1. Chistodouleas J and **Chan TA**. Optic pathway gliomas. ***Radiation Oncology: A Question-based Review***. Ed. Hristov, Lin, Christodouleas. 2010 Lippincott Williams & Wilkins.
2. Hristov B and **Chan TA**. Clinical management of pituitary tumors. ***Radiation Oncology: A Question-based Review***. Ed. Hristov, Lin, Christodouleas. 2010 Lippincott Williams & Wilkins.
3. Lin S and **Chan TA**. Management of CNS lymphomas. ***Radiation Oncology: A Question Based Review***. Ed. Hristov, Lin, Christodouleas. 2010 Lippincott Williams & Wilkins.
4. Hristov B and **Chan TA**. Primary spinal cord tumor. ***Radiation Oncology: A Question-based Review***. Ed. Hristov, Lin, Christodouleas. 2010 Lippincott Williams & Wilkins.
5. Hristov B and **Chan TA**. Choroid plexus carcinoma and papilloma. ***Radiation Oncology: A Question-based Review***. Ed. Hristov, Lin, Christodouleas. 2010 Lippincott Williams & Wilkins.
6. Laufer M and **Chan TA**. DNA Methylation. Chapter in Gelmann, ***Molecular Oncology: causes of cancer and targets for treatment*** 2011 Cambridge University Press.
7. **Chan TA**, Hristov B, Powell S. "Radiation Biology for Radiation Oncologists." Chapter in ***Clinical Radiation Oncology***. 2012 Elsevier BV.

Date: June 6, 2016

Signature:

